Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07360678

Comparing the Garmin Venu 3 / Garmin Venu 4 for Non-Invasive Vital Sign Monitoring to a Hospital-Grade Monitor

This clinical trial evaluates the accuracy of the Garmin Venu 3 / Garmin Venu 4 smartwatch in measuring vital signs (heart rate, respiratory rate, SpO₂) compared to the clinically validated Philips IntelliVue X2. The study aims to determine whether the consumer-grade smartwatch can provide reliable data for remote patient monitoring, early hospital discharge, and chronic disease management, offering a more accessible and affordable alternative to MDR-certified devices.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Ziekenhuis Oost-Limburg

Genk, 3600, Belgium

Location status: Recruiting

Location contact

David Ruttens, MD, PhD

PRINCIPAL_INVESTIGATOR

Future Health

CONTACT

[email protected]

+32 89 80 40 10

About this study

Wearable technology has rapidly evolved from fitness tracking tools to potential clinical-grade devices capable of non-invasive monitoring of vital signs. Among these, smartwatches equipped with optical sensors and accelerometers now offer continuous measurements of parameters such as heart rate, respiratory rate, and blood oxygen saturation (SpO2). The Garmin Venu 3 / Garmin Venu 4 represent a new generation of commercially available smartwatches that provide vital sign monitoring outside of controlled medical environments.

Despite their growing popularity and technological advancements, the clinical validity of smartwatches remains unknown. Applying for medical device regulation (MDR) certification is a long and expensive process, something not all companies can or want to invest in. Besides, the devices that are MDR certified are often very expensive, something not possible to use in an average patient population without extensive funding. For the use of (non-MDR certified) smartwatches into clinical workflows or remote patient monitoring systems, these devices must demonstrate accuracy and reliability comparable to gold-standard hospital-grade monitors.

The Philips IntelliVue X2 is a widely used and clinically validated multi-parameter patient monitoring system employed in acute care setting. It provides high-fidelity, real-time monitoring of vital signs and serves as an appropriate benchmark for evaluating the performance of customer-grade devices.

Comparing measurements obtained with the Garmin Venu 3 / Garmin Venu 4 against the IntelliVue X2 is essential to determine whether the smartwatch can serve as a reliable tool for continuous vital sign tracking in real-world clinical scenarios. This is particularly relevant for use cases such as early hospital discharge, remote patient monitoring and chronic disease management where accessibility, affordability, convenience and user compliance are critical.

This clinical trial seeks to assess the agreement and accuracy of the Garmin Venu 3 / Garmin Venu 4 in measuring key physiological parameters such as heart rate, respiratory rate, and SpO2 compared to the Philips Intellivue X2 in a diverse patient population. Demonstrating clinical equivalence or acceptable accuracy margins would support the potential use of the Garmin Venu 3 / Garmin Venu 4 in remote or supplemental monitoring roles within modern (hybrid) healthcare systems.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Provide signed and dated informed consent
  • Adults older than 18 years of age
  • Speak and understand the Dutch language
  • Hospitalized for at least another 24 hours

Exclusion criteria

  • Life expectancy is less than 30 days
  • Patient is isolated due to infection control

Treatment and study plan

Garmin Venu 3 or Garmin Venu 4 + Philips Intellivue X2

Device

Each participant will be continuously monitored for a minimum of one full night and up to a maximum of 24 hours using both a hospital-grade monitor (Philips IntelliVue X2) and a Garmin Venu 3 or Garmin Venu 4 smartwatch.

Smartwatch rating scale questionnaire

Other

Upon completion of the monitoring period, participants will be asked to complete the Smartwatch Rating Scale (SRS) questionnaire

Primary outcomes

  1. Mean absolute difference between the Garmin Venu 3 / Garmin Venu 4 and a hospital-grade monitor in measuring heart rate up to 24 hours.

    Time frame: From enrollment to the end of treatment at 24 hours

    For heart rate, the mean absolute difference will be calulated between the measurements performed with the Garmin Venu 3 / Garmin Venu 4 and the measurements performed with the Philips Intellivue X2

  2. Mean absolute difference between the Garmin Venu 3 / Garmin Venu 4 and a hospital-grade monitor in measuring respiratory rate up to 24 hours.

    Time frame: From enrollment to the end of treatment at 24 hours

    For respiratory rate, the mean absolute difference will be calculated between the measurements performed with the Garmin Venu 3 / Garmin Venu 4 and the measurements performed with the Philips IntelliVue X2

  3. Mean absolute difference between the Garmin Venu 3 / Garmin Venu 4 and a hospital-grade monitor in measuring peripheral oxygen saturation up to 24 hours.

    Time frame: From enrollment to the end of treatment at 24 hours

    For peripheral oxygen satuation (SpO2), the mean absolute difference will be calculated between the measurements performed with the Garmin Venu 3 / Garmin Venu 4 and the measurements performed with the Philips IntelliVue X2.

Secondary outcomes

  1. User experience of the Garmin Venu 3 / Garmin Venu 4 as measured by the Smartwatch Rating Scale

    Time frame: From enrollment to the end of treatment at 24 hours

    User experience of the Garmin Venu 3 / Garmin Venu 4 as measured by the Smartwatch Rating Scale

  2. Number of artefacts during measurements performed when the participant is awake vs measurements performed when the participant is asleep (expressed in % measurements)

    Time frame: From enrollment to the end of treatment at 24 hours

    Measurements reported as a '0' due to the inability of the device to perform a correct measurement will be labeled as false.

  3. Time to detection of a sudden drop in SpO2 or clinical deterioration measured by the Garmin Venu 3 / Garmin Venu 4 vs a hospital-grade monitor

    Time frame: From enrollment to the end of treatment at 24 hours

    In the event of patient deterioration, changes may be reflected in SpO2 levels. This endpoint will evaluate the time taken by the Garmin Venu 3 / Garmin Venu 4 compared to a hospital-grade monitor to detect such changes.

Study contacts

Contact information is provided by the study sponsor or research team.

Femke Wouters, PhD

CONTACT

[email protected]

+32 89 80 40 32

Ruben Knevels, MSc

CONTACT

[email protected]

+32 89 80 40 29

Sponsors and collaborators

Lead sponsor

Ziekenhuis Oost-Limburg

Other

Registry information

Acronym: GARMIN

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jan 22, 2026
Registry last updated
Feb 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.